Wen Liu, MD
Internal Medicine · Shreveport, LANPI 1336328202
Payments from drug & device makers
Across 331 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Johnson & Johnson$870
- E.r. Squibb & Sons, L.L.C.$365
- Merck$342
- Novartis$284
- Novo Nordisk$264
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,78895%
- Education$2815%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 98 | $1,699 |
| Johnson & Johnson | 46 | $870 |
| E.r. Squibb & Sons, L.L.C. | 23 | $365 |
| Merck | 23 | $342 |
| Novartis | 16 | $284 |
| Novo Nordisk | 16 | $264 |
| Pfizer | 13 | $235 |
| Astellas Pharma US Inc | 4 | $218 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $154 |
| Lilly USA, LLC | 8 | $152 |
| Sanofi-aventis U.S. LLC | 9 | $132 |
| Tactile Systems Technology Inc | 1 | $130 |
| Paratek Pharmaceuticals, Inc. | 6 | $126 |
| Bayer | 6 | $113 |
| Antares Pharma, Inc. | 6 | $104 |
| Mallinckrodt Hospital Products Inc. | 4 | $80 |
| Medtronic | 2 | $77 |
| Phathom Pharmaceuticals, Inc. | 4 | $69 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| Melinta Therapeutics, LLC | 4 | $64 |
| Shire North American Group Inc | 3 | $61 |
| Abbott | 4 | $59 |
| GSK | 3 | $58 |
| Boehringer Ingelheim | 3 | $54 |
| Daiichi Sankyo Inc. | 2 | $44 |
| UCB, Inc. | 1 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| AbbVie | 2 | $31 |
| Amgen(2 entities) | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Corcept Therapeutics | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flexitouch Plus$130
- ENTRE$130
How this compares
$6,069 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $243,809 |
| EliquisApixaban | 149 | $132,529 |
| MounjaroTirzepatide | 94 | $114,505 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $93,881 |
| JardianceEmpagliflozin | 68 | $66,717 |
| TrulicityDulaglutide | 40 | $51,566 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $34,212 |
| XareltoRivaroxaban | 25 | $27,152 |
| FarxigaDapagliflozin Propanediol | 22 | $26,715 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $26,211 |
| MyrbetriqMirabegron | 20 | $23,789 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $23,195 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $19,595 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $15,294 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $13,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $264 | $243,809147 claims |
| Lilly USA, LLCMounjaro, Trulicity | $152 | $166,072134 claims |
| PfizerEliquis | $235 | $132,529149 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $54 | $86,31379 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $58 | $39,71140 claims |
| Johnson & JohnsonXarelto | $870 | $27,15225 claims |
| AstraZenecaFarxiga | $1,699 | $26,71522 claims |
| Astellas Pharma US IncMyrbetriq | $218 | $23,78920 claims |
| MerckJanumet | $342 | $15,29415 claims |
| AbbVieSynthroid | $31 | $4,23256 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Shreveport
- Deepika RallaShreveport$261K
- Maliha AgloriaShreveport$181K
- Bharat SachdevaShreveport$165K
- Rajan KhannaShreveport$59K
- Ishak MansiShreveport$53K
- Wendell WallShreveport$25K
- Attila BaloghShreveport$18K
- Ammar AlqaidShreveport$18K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.